Ben Burnett's questions to Allogene Therapeutics Inc (ALLO) leadership • Q4 2024
Question
Carolina Ibanez-Ventoso on for Ben Burnett asked for the specific timing of the MRD conversion measurement for the mid-2025 interim analysis of the cema-cel ALPHA3 trial.
Answer
EVP of R&D and CMO Dr. Zachary Roberts responded that the company has not disclosed the exact timing of the MRD sample draw. He also noted that the lymphodepletion decision will be based on an assessment of multiple elements, not just the MRD conversion data.